LEO Pharma

LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | LEO PharmaPressemeddelelse

The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.
Innovationsfonden

AI skal forudsige og forklare behov for vedligeholdelse af maskiner17.11.2025 08:00:00 CET | InnovationsfondenPressemeddelelse

Datalogisk Institut på KU, DTU Compute, Metroselskabet, Everllence og DCR Solutions går sammen om at løse en af de centrale udfordringer i Industri 4.0: Nemlig hvordan man kan bruge de mange data, der i dag opsamles fra moderne maskiner, til at give forklarlige forudsigelser for vedligeholdelse, der kan omsættes til handling. Innovationsfonden investerer godt 19 mio. kr. i projektet over 4 år.
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye